Presentation Information
[1P-869]Prediction of resistance mutations against Zotizalkib and Gilteritinib in second-line therapy for ALK-positive lung cancer
○Yuki Takei1, Chisaki Arai1, Yuta Doi1, Kentaro Semba1,2 (1. Sch. of Adv. Sci. & Eng., Waseda Univ., 2. Translational Research Center, Fukushima Medical Univ.)
Password required to view
orLog in
Comment
To browse or post comments, you must log in.Log in